Texas (September 15, 2013) Wax Ink has issued a Negative Investment Interest opinion for Edwards Lifesciences Corporation (NYSE: EW) based on a recent baseline equity review which placed fair value between $44-$53.
The recent close of $71.61 is approximately 169% above the fair value buy target for the stock and approximately 31% above the fair value close target for the stock. The recent close is also 6% below analysts' twelve-month $76.00 median price target for the stock.
The recent close represents an 32% decrease in the one year price of the stock, while year-over-year sales decreased 13%, year-over-year earnings increased 19%, and year-over-year debt increased 27%.
The stock currently has a trailing twelve-month PE Ratio of 23, and a PEG Ratio of 1.4 basis estimated forward earnings growth of 17%.
In the past 52 weeks, share prices have moved between a high of $110.79 and a low of $62.34, placing equilibrium at $74.29.
With the recent close, the stock is trading 55% below the 52 week high, 13% above the 52 week low, and 4% below equilibrium.
The three-month average daily trading volume for the stock is approximately 962,000 shares.
The company's listed competitors include ICU Medical, Medtronic,and St. Jude Medical.
Financial information that may be contained herein, is based on the company's most recent annual SEC filing for year ending December 31, 2012.
All prices are per share unless otherwise noted.
Wax Ink currently has no investment position in any company mentioned in this alert.
For use by Accredited Investors as defined under Title 17, CFR §230.500, Regulation D.
Copyright © 2013 Wax Ink
Wax Ink is a baseline equity research company not licensed or registered with any government agency
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.